Virucidal Effect of PVP-I on COVID-19 and as Well as Safety of Its Application on Nasopharynx & Oropharynx

Conditions

• Virus Infection, RNA
• Effect of Drug
• Efficacy, Self

Interventions

• DRUG: 0.6% PVP-I oral and nasal spray to moderately ill COVID-19 positive patient
• DRUG: 0.6% PVP-I Oral and nasal spray to asymptomatic to mild COVID-19 patient having multiple comorbidity
• DRUG: 0.6% PVP-I Oral and nasal spray to healthy volunteer
• OTHER: Oral and nasal spray by distilled water to control group

Sponsor

DR. MALA KHAN

Collaborators

• [object Object]